

Quick Start Manual FDALabel Database

https://www.fda.gov/science-research/bioinformatics-tools/fdalabelfull-text-search-drug-labeling (home page)

https://nctr-crs.fda.gov/fdalabel/ui/search (launch database)

Dec. 2020

National Center for Toxicological Research (NCTR)
U.S. Food and Drug Administration (FDA)

FDA LABEL

What is FDALabel?

- Free web-based database for managing, querying and organizing drug product labeling information
- Database of over 130,000 FDA Structured Product Labelings (SPL)
- Includes human prescription, biological, over-the-counter (OTC), and animal drug product labeling documents
- User-friendly interface with full-text labeling search, customizable search, and all labeling section search
- Updated monthly from FDA's SPL archive (hosted by DailyMed)
- A secure 3-tier platform web application with Oracle database
- Developed and maintained at NCTR (National Center for Toxicological Research) since 2012
- Most popular NCTR/FDA Bioinformatics tool: https://www.fda.gov/science-research/bioinformatics-tools

FDALabel Database Key Features

- Search using a single field (e.g., full-text search, product or generic name search) or use a combination of fields to create advanced searches including:
 - Document types (e.g., Human Rx, OTC, Animal Rx)
 - Marketing categories (e.g., ANDA, BLA, NDA)
 - Presence of, or text within, specific sections of the prescribing information (e.g., BOXED WARNING, INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS, DRUG INTERACTIONS)
 - Pharmacologic class(es)
 - MedDRA terminologies
 - Chemical structure and similarity search
 - SPL identifiers (e.g., Product NDC Codes and SET IDs)
- Summary statistics and total labelings counts by specific sections
- Export and save summary results in spreadsheet format (Excel)
- Create, save, share permanent query links to replicate searches
- User Support Team to answer questions or assist with queries

Example Questions Answered Using FDALabel

- What drug labelings include a Boxed Warning section with keywords "acute liver failure"?

 Query Results
- What drug products are indicated for type 2 diabetes mellitus?

 Query Results
- How many drug labelings contain the MedDRA PT term "acute kidney injury" and related LTTs? Query Results
- What drugs share the same pharmacologic drug class (e.g., beta-Adrenergic Blocker)?

 Query

 Results


FDALabel Interface Overview

1-7 Default search panels

8 Add more criteria


9 Start search

Additional Search Panels




User Case 1: Full Text Search

Search for Human Prescription Drug and New Drug Application that have acute liver failure



Results Page Overview

68 Labeling Results for Human Rx and NDA with acute liver failure



^{*}SPL counts shown in manual are accurate as of Dec. 2020

SPL Highlighted Terms

Full Text search for "acute liver failure" AND "hepatitis"

5.3 Hepatotoxicity

Search terms are highlighted in SPL

Hepatic adverse events have been reported in patients receiving a dolutegravir-containing regimen [see Adverse Reactions (6.1)]. Patients with underlying hepatitis B or C may be at increased risk for worsening or development of transaminase elevations with use of TRIUMEQ [see Adverse Reactions (6.1)]. In some cases, the elevations in transaminases were consistent with immune reconstitution syndrome of hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn. Cases of hepatic toxicity including elevated serum liver biochemistries, hepatitis and acute liver failure have also been reported in patients receiving a dolutegravir-containing regimen who had no pre-existing hepatic disease or other identifiable risk factors. Drug-induced liver injury leading to liver transplant has been reported with TRIUMEQ. Monitoring for hepatotoxicity is recommended.


5.3 Hepatotoxicity

Click on a term to remove highlights

Hepatic adverse events have been reported in patients receiving a dolutegravir-containing regimen [see Adverse Reactions (6.1)]. Patients with underlying hepatitis I) or C may be at increased risk for worsening or development of transaminase elevations with use of TRIUMEQ [see Adverse Reactions (6.1)]. In some cases, the elevations in transaminases were consistent with immune reconstitution syndrome of hepatitis B reactivation particularly in the setting where anti-hepatitis therapy was withdrawn. Cases of hepatic toxicity including elevated serum liver biochemistries, hepatitis, and acute liver failure have also been reported in patients receiving a dolutegravir-containing regimen who had no pre-existing hepatic disease or other identifiable risk factors. Drug-induced liver injury leading to liver transplant has been reported with TRIUMEQ. Monitoring for hepatotoxicity is recommended.


Permanent Query Link

Use Permanent Query Link to save, share, replicate, or modify queries




User Case 2: Section Search

Search for Human Prescription Drug and New Drug Application that have acute liver failure within the BOXED WARNING




User Case 3: Product Search

Search for **Human Prescription Drug** and **New Drug Application** and drug products with the name **Amoxicillin**




User Case 4: Pharmacologic Class

Search for Human Prescription Drug and New Drug Application in the beta-Adrenergic Blocker pharmacologic class



User Case 5: MedDRA Term Search

Search for Human Prescription Drug and New Drug Application and MedDRA preferred term Acute kidney injury



FDALabel Support and Information

FDALabel Public Version (Hosted on Amazon Cloud)

https://nctr-crs.fda.gov/fdalabel/ui/search

FDALabel Public Homepage

https://www.fda.gov/science-research/bioinformatics-tools/fdalabel-full-text-search-drug-labeling

Contact Support

Comments, Suggestions, Questions: Hong Fang Hong.Fang@fda.hhs.gov

Technical Support: Steve Harris Stephen. Harris@fda.hhs.gov

User Support: Taylor Ingle Taylor.Ingle@fda.hhs.gov

Additional Information

FDALabel Resources

Simple Search Guide

Advanced Search Guide

Query Logic Guide

Publications

Fang, H. et al. FDALabel for drug repurposing studies and beyond. *Nat Biotechnol* 38; 1378-1379 (2020). <u>Abstract</u>

Mehta, D. et al. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine. *Drug Discov Today* 25(5):813-820 (2020). Abstract

Wu, L. et al. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA. *BMC Bioinformatics* 14;20(Suppl 2):97 (2019). Abstract

Fang, H. et al. FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science. *Drug Discov Today* 21(10):1566-1570 (2016). Abstract